CAARLOGIC BIOMED CO. LTD.

Area: Government, Academia and Research Institutes

Booth No: M534

Exhibitor Profile

Caarlogic Biomed is dedicated to advancing next-generation CAR-T therapies, aiming to significantly enhance efficacy and safety for patients with tumors and autoimmune diseases. Our core "CAR x CCR Modular Hybrid-Receptor Platform" integrates a primary receptor (single-chain Chimeric Antigen Receptor, CAR) and a secondary receptor (multi-chain Chimeric Co-stimulation Receptor, CCR), providing advanced T-cell functional signaling. Beyond platform development, Caarlogic has highly optimized genetic engineering tools and manufacturing processes to ensure patients receive the maximum benefit from CAR x CCR-T cell therapy. Caarlogic will launch its debut with the exceptional BCMA x ISER-T as its lead product for the treatment of multiple myeloma.
CAR x CCR platform features five core highlights:
1. Hybrid A-DASH Dual-Receptor Design: A hierarchical CAR x CCR activation mechanism that precisely regulates signaling like a hybrid vehicle, ensuring high efficacy while preventing premature cell exhaustion.
2. TME Remodeling: Clears immunosuppressive cells (e.g., MDSCs, CAFs) to reshape the tumor microenvironment.
3. Alpaca VHH binders: Utilize proprietary alpaca single-domain antibodies to deliver high tumor-killing efficacy and an enhanced safety profile.
4. Advanced Immune Synapse Enhancement: Promotes the formation and structural stability of the immune synapse, and prevents tumor escape.
5. Optimized 3rd lentiviral packing system: Produces high viral yield for large-sized CAR x CCR construct and minimizes cost.